newsfilter
← Latest News
ACCESS Newswire·

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics , a leader in the